{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:02:19Z","timestamp":1790791339069,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":395,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Guideline-directed medical therapy (GDMT) is recommended for all patients with heart failure with reduced ejection fraction (HFrEF). Despite this, little data exist describing GDMT use in diverse, real-world populations including the use of vasodilators, prescribed primarily to Black populations. We sought, among a diverse population of HFrEF patients, to determine (1) GDMT use rates and target dosing by medication class and (2) predictors of GDMT use and target dosing by medication class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized electronic health records (EHRs) from Kaiser Permanente (KP) Mid-Atlantic States, a large integrated health system. Included patients had heart failure and left ventricular ejection fraction (EF) of \u226440% between 2015 and 2021. GDMT was defined by five medication classes\u2014angiotensin-converting enzyme (ACE) inhibitors (ACEis)\/angiotensin receptor blockers (ARBs)\/angiotensin receptor\u2013neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) and vasodilators (Black patients only). Proportions of patients on GDMT and target dose rates were examined. Logistic regression determined, within each class, predictors of medication use and being at \u226580% of the target dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3154 patients were included. Among the 93.8% on some form of GDMT, 82.8%, 81.4%, 23.5%, 3.6% and 13.4% were on ACEis\/ARBs\/ARNis, BBs, MRAs, SGLT2is and vasodilators (Black patients only), respectively. Among treated patients, 45.8%, 21.4%, 77.6%, 100% and 14.7% were treated at \u226580% of the target dose for ACEis\/ARBs\/ARNis, BBs, MRAs, SGLT2is and vasodilators, respectively. Overall, increasing age, higher EF, atrial fibrillation\/flutter, chronic obstructive pulmonary disease (COPD), prior stroke and dementia were associated with decreased odds of GDMT use. Conversely, higher body mass index (BMI), Black race, higher glomerular filtration rate (GFR), recent echo and cardiac defibrillator were associated with increased odds of GDMT use. Among treated, higher BMI, higher systolic blood pressure, haemoglobin A1C \u2265 6.5% and cardiac defibrillator were associated with higher odds of being at \u226580% of the target dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study using real-world data from a diverse health system demonstrated gaps in GDMT use among patients with HFrEF, specifically older patients with more comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15193","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T01:56:29Z","timestamp":1737338189000},"page":"1861-1871","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Guideline-Directed Medical Therapy Rates in Heart Failure Patients witH Reduced Ejection Fraction in a Diverse Cohort"],"prefix":"10.1093","volume":"12","author":[{"given":"Natalia C.","family":"Berry","sequence":"first","affiliation":[{"name":"Department of Cardiology, Mid-Atlantic Permanente Medical Group , McLean, Virginia ,","place":["USA"]},{"name":"Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shin","family":"Sheu","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chesbrough","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Clayton","family":"Bishop","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Vupputuri","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"key":"2026021804263458900_ehf215193-bib-0001","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0002","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/cir.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2026021804263458900_ehf215193-bib-0003","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"Hjalmarson","year":"1999","journal-title":"Lancet"},{"key":"2026021804263458900_ehf215193-bib-0004","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Lechat","year":"1999","journal-title":"Lancet"},{"key":"2026021804263458900_ehf215193-bib-0005","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026021804263458900_ehf215193-bib-0006","doi-asserted-by":"publisher","first-page":"60a","DOI":"10.1016\/s0002-9149(88)80087-0","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"62","author":"Swedberg","year":"1988","journal-title":"Am J Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0007","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/nejm199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0008","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0009","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0010","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0011","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0012","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0013","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0014","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0015","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/nejm198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0016","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021804263458900_ehf215193-bib-0017","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804263458900_ehf215193-bib-0018","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0019","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0020","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2017.04.010","article-title":"Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry","volume":"189","author":"DeVore","year":"2017","journal-title":"Am Heart J"},{"key":"2026021804263458900_ehf215193-bib-0021","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"key":"2026021804263458900_ehf215193-bib-0022","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"key":"2026021804263458900_ehf215193-bib-0023","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1161\/circulationaha.105.577577","article-title":"Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study","volume":"113","author":"Go","year":"2006","journal-title":"Circulation"},{"key":"2026021804263458900_ehf215193-bib-0024","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/CIRCOUTCOMES.113.000221","article-title":"Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study","volume":"6","author":"Smith","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021804263458900_ehf215193-bib-0025","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.amjcard.2004.07.081","article-title":"Gender and risk of adverse outcomes in heart failure","volume":"94","author":"Lee","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0026","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection\u2014a review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"key":"2026021804263458900_ehf215193-bib-0027","volume-title":"Python 3.10.0","author":"Python","year":"2021"},{"key":"2026021804263458900_ehf215193-bib-0028","volume-title":"Statsmodels: econometric and statistical modeling with Python","author":"Seabold","year":"2010"},{"key":"2026021804263458900_ehf215193-bib-0029","doi-asserted-by":"crossref","DOI":"10.25080\/Majora-92bf1922-00a","volume-title":"Data structures for statistical computing in Python","author":"McKinney","year":"2010"},{"key":"2026021804263458900_ehf215193-bib-0030","volume-title":"Matplotlib: a 2D graphics environment","author":"Hunter","year":"2007"},{"key":"2026021804263458900_ehf215193-bib-0031","volume-title":"Seaborn: statistical data visualization","author":"Waskom","year":"2021"},{"key":"2026021804263458900_ehf215193-bib-0032","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/circulationaha.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)","volume":"122","author":"Fonarow","year":"2010","journal-title":"Circulation"},{"key":"2026021804263458900_ehf215193-bib-0033","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/circulationaha.123.067489","article-title":"Sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction","volume":"149","author":"Sumarsono","year":"2024","journal-title":"Circulation"},{"key":"2026021804263458900_ehf215193-bib-0034","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0035","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ejhf.3267","article-title":"Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study","volume":"26","author":"Malgie","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0036","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/circoutcomes.109.879478","article-title":"Treatment and risk in heart failure: gaps in evidence or quality?","volume":"3","author":"Peterson","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026021804263458900_ehf215193-bib-0037","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021804263458900_ehf215193-bib-0038","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1002\/ehf2.12827","article-title":"Frailty and the risk of all-cause mortality and hospitalization in chronic heart failure: a meta-analysis","volume":"7","author":"Uchmanowicz","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0039","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jchf.2019.10.003","article-title":"Frailty among older decompensated heart failure patients: prevalence, association with patient-centered outcomes, and efficient detection methods","volume":"7","author":"Pandey","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0040","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jchf.2021.12.004","article-title":"Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial","volume":"10","author":"Khan","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0041","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jchf.2023.03.007","article-title":"Polypharmacy and optimization of guideline-directed medical therapy in heart failure: the GUIDE-IT trial","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0042","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0043","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jacc.2023.12.033","article-title":"Implications of atrial fibrillation for guideline-directed therapy in patients with heart failure: JACC state-of-the-art review","volume":"83","author":"Newman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0044","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s40615-021-01202-5","article-title":"Racial differences in trends and prognosis of guideline-directed medical therapy for heart failure with reduced ejection fraction: the Atherosclerosis Risk in Communities (ARIC) surveillance study","volume":"10","author":"Mathews","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026021804263458900_ehf215193-bib-0045","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jchf.2023.08.027","article-title":"Patterns, prognostic implications, and rural-urban disparities in optimal GDMT following HFrEF diagnosis among Medicare beneficiaries","volume":"12","author":"Mentias","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0046","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s40615-021-00984-y","article-title":"Prevalence of guideline-directed medical therapy for cardiovascular disease among Baltimore City adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) study","volume":"9","author":"Mathews","year":"2022","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026021804263458900_ehf215193-bib-0047","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.009014","article-title":"Sex and race differences in the utilization and outcomes of coronary artery bypass grafting among Medicare beneficiaries, 1999\u20132014","volume":"7","author":"Angraal","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026021804263458900_ehf215193-bib-0048","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1001\/jama.1993.03500200056033","article-title":"Racial differences in the use of revascularization procedures after coronary angiography","volume":"269","author":"Ayanian","year":"1993","journal-title":"JAMA"},{"key":"2026021804263458900_ehf215193-bib-0049","first-page":"317","article-title":"Racial and ethnic disparities in cardiac catheterization for acute myocardial infarction in the United States, 1995\u20132001","volume":"97","author":"Bertoni","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"2026021804263458900_ehf215193-bib-0050","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.119.006214","article-title":"Identification of racial inequities in access to specialized inpatient heart failure care at an academic medical center","volume":"12","author":"Eberly","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026021804263458900_ehf215193-bib-0051","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.amjcard.2019.09.020","article-title":"Comparison of hydralazine\/nitrate and angiotensin receptor neprilysin inhibitor use among black versus nonblack Americans with heart failure and reduced ejection fraction (from CHAMP-HF)","volume":"124","author":"Giblin","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026021804263458900_ehf215193-bib-0052","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.02","article-title":"Unequitable heart failure therapy for Black, Hispanic and American-Indian patients","volume":"8","author":"Ilonze","year":"2022","journal-title":"Card Fail Rev"},{"key":"2026021804263458900_ehf215193-bib-0053","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1861\/66956185\/eschf_12_3_1861.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1861\/66956185\/eschf_12_3_1861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:26:37Z","timestamp":1771406797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/1861\/8488351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,19]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15193","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,19]]},"assertion":[{"value":"2024-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}